Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01209442 · ClinicalTrials.gov registry record · Phase 2
Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme
A Phase 2 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT01209442 is a Phase 2 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 30 participants.
The verdict
NCT01209442, a Phase 2 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to find out whether Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) combining with temozolomide chemotherapy can be safely given with a targeted agent, bevacizumab, and how effective this study treatment will be in controlling your brain tumor.
Interventions
- DRUG Bevacizumab
- DRUG Temozolomide
- RADIATION RT (Radiation Therapy)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2010-09-16 |
| Est. Completion | 2017-02-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01209442
The ClinicalTrials.gov registry entry for NCT01209442 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT01209442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01209442 about?
NCT01209442 is a clinical study titled "Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme". The purpose of this study is to find out whether Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) combining with temozolomide chemotherapy can be safely given with a targeted agent, bevacizumab, and how effective this study treatment will be in controlling your brain tumor.
What is the current status of trial NCT01209442?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2010-09-16. Estimated completion is 2017-02-03.
What interventions are being tested in trial NCT01209442?
The interventions under investigation include: Bevacizumab (DRUG), Temozolomide (DRUG), RT (Radiation Therapy) (RADIATION).
Who is sponsoring clinical trial NCT01209442?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.